Oxford Biomedica PLC Director/PDMR Shareholding (1724K)
04 May 2022 - 1:46AM
UK Regulatory
TIDMOXB
RNS Number : 1724K
Oxford Biomedica PLC
03 May 2022
PDMR Dealings
Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford
Biomedica" or "the Company") (LSE: OXB), was informed on 03 May
2022, that Dr. Jason Slingsby, Chief Business & Corporate
Development Officer of the Group, exercised 8,712 LTIP (2018)
options at nil cost on 27 April 2022, and sold all the resulting
ordinary shares at 539.0p per share. Following this transaction Dr.
Jason Slingsby continues to hold 120,476 options over ordinary
shares.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of Ordinary Shares sold.
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Jason Slingsby
----------------------------- ---------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position/status Chief Business & Corporate Development
Officer
----------------------------- ---------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ---------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------
a) Name Oxford BioMedica plc
----------------------------- ---------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ---------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
----------------------------------------------------------------------
a) Description of Options over ordinary Shares of 50
the financial pence each
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- ---------------------------------------
b) Nature of the Exercise of options at nil cost
transaction
----------------------------- ---------------------------------------
c) Currency GBP - British pound
----------------------------- ---------------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
Nil 8,712
----------
----------------------------- ---------------------------------------
e) Aggregated information 8,712
* Aggregate volume Nil
Nil
* Price
* Aggregated total
----------------------------- ---------------------------------------
f) Date of the transaction 2022-04-27
----------------------------- ---------------------------------------
g) Place of the transaction Outside a trading venue
----------------------------- ---------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Jason Slingsby
----------------------------- ---------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position/status Chief Business & Corporate Development
Officer
----------------------------- ---------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ---------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------
a) Name Oxford BioMedica plc
----------------------------- ---------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ---------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
----------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ---------------------------------------
b) Nature of the Disposal
transaction
----------------------------- ---------------------------------------
c) Currency GBP - British pound
----------------------------- ---------------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP5.39 8,712
----------
----------------------------- ---------------------------------------
e) Aggregated information 8,712
* Aggregate volume GBP5.39
GBP46,957.68
* Price
* Aggregated total
----------------------------- ---------------------------------------
f) Date of the transaction 2022-04-27
----------------------------- ---------------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- ---------------------------------------
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector
specialist focused on delivering life changing therapies to
patients.
Oxford Biomedica plc and its subsidiaries (the Group) work
across key viral vector delivery systems including those based on
lentivirus, adeno-associated virus (AAV) and adenovirus, providing
innovative solutions to cell and gene therapy biotechnology and
biopharma companies for their process development, analytical
development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector(R)
platform, which the Group leverages to develop product candidates
in-house, before seeking partners to take the products into
clinical trials.
Oxford Biomedica is based across several locations and
headquartered in Oxfordshire, UK. In early 2022, the Group
established Oxford Biomedica Solutions, a new US based subsidiary
AAV manufacturing and innovation business, based near Boston,
US.
Oxford Biomedica employs more than 940 people. Further
information is available at www.oxb.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBUGDUDSGDGDX
(END) Dow Jones Newswires
May 03, 2022 11:46 ET (15:46 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024
